Enzo Biochem, Inc. (NYSE:ENZ) major shareholder Harbert Management Corp acquired 22,800 shares of the business’s stock in a transaction on Friday, August 16th. The shares were purchased at an average price of $3.06 per share, with a total value of $69,768.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.
Harbert Management Corp also recently made the following trade(s):
- On Monday, July 22nd, Harbert Management Corp acquired 9,644 shares of Enzo Biochem stock. The shares were purchased at an average price of $3.64 per share, with a total value of $35,104.16.
- On Tuesday, May 28th, Harbert Management Corp acquired 63,677 shares of Enzo Biochem stock. The shares were purchased at an average price of $3.09 per share, with a total value of $196,761.93.
NYSE:ENZ opened at $3.14 on Friday. The company has a quick ratio of 5.12, a current ratio of 5.61 and a debt-to-equity ratio of 0.05. Enzo Biochem, Inc. has a fifty-two week low of $2.32 and a fifty-two week high of $5.00. The firm’s fifty day simple moving average is $3.64 and its 200-day simple moving average is $3.46.
Large investors have recently bought and sold shares of the company. Northern Trust Corp lifted its holdings in Enzo Biochem by 1.3% in the 2nd quarter. Northern Trust Corp now owns 562,106 shares of the medical research company’s stock worth $1,895,000 after purchasing an additional 7,158 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in shares of Enzo Biochem during the second quarter worth approximately $26,000. BNP Paribas Arbitrage SA lifted its holdings in shares of Enzo Biochem by 1,298.2% during the first quarter. BNP Paribas Arbitrage SA now owns 9,242 shares of the medical research company’s stock worth $25,000 after buying an additional 8,581 shares during the last quarter. KBC Group NV lifted its holdings in shares of Enzo Biochem by 128.8% during the second quarter. KBC Group NV now owns 17,048 shares of the medical research company’s stock worth $57,000 after buying an additional 9,598 shares during the last quarter. Finally, Corient Capital Partners LLC acquired a new position in shares of Enzo Biochem during the first quarter worth approximately $31,000. 63.08% of the stock is currently owned by institutional investors and hedge funds.
Separately, TheStreet upgraded shares of Enzo Biochem from a “d” rating to a “c-” rating in a research report on Tuesday, July 2nd.
About Enzo Biochem
Enzo Biochem, Inc, an integrated diagnostic bioscience company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates in three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics.
Featured Article: How does equity income fit into an investing strategy?
Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.